

REVIEW

Open Access

# Quality problems of clinical trials in China: evidence from quality related studies



Jin Fan<sup>1,2†</sup>, Xiaobo Liu<sup>1,2†</sup>, Yuxi Li<sup>1,2</sup>, Haisha Xia<sup>1,2</sup>, Rong Yang<sup>1</sup>, Juan Li<sup>1,2</sup> and Yonggang Zhang<sup>1,3,4\*</sup> 

## Abstract

**Background:** Recently, the quality of clinical trials conducted in China has made considerable progress. However, clinical trials conducted in China still fall below the global average standard. The aim of this systematic review was to assess studies that investigated the quality of clinical trials conducted in China, summarize the issues, and provide suggestions for conducting high-quality clinical trials in China.

**Methods:** We comprehensively searched studies that investigated the quality of clinical trials conducted in China in the following databases from inception to December 1, 2021: National Knowledge Infrastructure, the Chinese Science and Technology Periodical Database, WanFang Data, China Biology Medicine, PubMed, and Embase. We then analyzed the issues in clinical trial registration, ethics review, implementation, and reporting. SPSS 25.0 software was used for data analysis. The data synthesis was conducted using summary statistics and a narrative format.

**Results:** A total of 90 studies were analyzed, there were 50 studies with 0–5 citation counts (55.56%), 18 studies with 5–10 citation counts (20%), 9 studies with 10–15 citation counts (10%), and 13 studies with more than 15 citation counts (14.44%). Eight (8.89%) studies were conducted by a supervision department, 38 (42.22%) by organizations with GCP qualification, and 44 (48.89%) by third parties. Additionally, there were some problems in the ethical review process of clinical trials, clinical trial registration process, clinical trial implementation process, and clinical trial reporting process.

**Conclusions:** The current study shows that the quality problems of clinical trials in China still exist. The reported problems are related to the process of clinical trials, including ethical review, registration, implementation, reporting. Due to the limited quantity and quality of included studies, the conclusions of this study need to be verified by high-quality studies.

**Review registration:** Not registered in PROSPERO.

**Keywords:** China, Clinical trials, Quality control, Systematic review

\* Correspondence: [jebm\\_zhang@yahoo.com](mailto:jebm_zhang@yahoo.com)

†Jin Fan and Xiaobo Liu contributed equally to this work and are co-first authors.

<sup>4</sup>Nursing Key Laboratory of Sichuan Province, Chengdu, China

Full list of author information is available at the end of the article



© The Author(s). 2022 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

## Background

Clinical trials are studies based on population, human body, or samples, such as tissues and fluids [1]. Evidence from clinical trials provides a meaningful reference for doctors and policymakers in health care [2]. With the rapid development of medicine in China, the quality of clinical trials conducted in China has made considerable progress. However, the quality were still needed to improve [3, 4].

High-quality clinical trials play an irreplaceable role in clinical decisions. However, the global quality of clinical trials is facing significant challenges. Transparency and quality control during the entire clinical trial process are the most important strategies to improve this situation [5]. On July 1, 2020, the China Food and Drug Administration (CFDA) and National Health Commission published a revised *Good Clinical Practice (GCP)* claiming “Criterion for the quality control of clinical trials of drugs is the quality standard for the whole process of drug clinical trials, including designing, organizing and implementing, supervising, inspecting, recording, analyzing, summarizing, and reporting.” Registering protocols, ensuring transparency, and reporting results accurately can improve the quality of clinical trials. Although clinical trials in China have improved through optimizing research design, strictly reviewing protocols, improving researchers’ ability, and enhancing quality supervision, quality problems still exist. Based on this situation, the aim of this study is to search studies related to the quality of clinical trials in China, systematically review the current status, and summarize the existing problems to provide a reference for researchers.

## Methods

### Protocol and registration

The systematic review was not registered in PROSPERO. This systematic review was reported according to the Preferred Reporting Items for Systematic reviews and Meta-Analysis 2020 (PRISMA 2020) statement guidelines [6]. A completed PRISMA checklist was available in supplementary material 1.

### Inclusion and exclusion criteria

This systematic review included reviews that evaluated problems of domestic clinical trials. The primary outcome was the problem reported in any part of the clinical trial process. Secondary outcomes were the frequency and composition ratio. Additionally, studies were excluded if they met any of the following criteria: no problems reported, duplicate publications, confined to a particular field or special drug, and related to a medical device.

### Search strategy

Two independent reviewers (YX-L and HS-X) systematically searched the following databases from inception to December 1, 2021: China National Knowledge Infrastructure, the Chinese Science and Technology Periodical Database, WanFang, China Biology Medicine, PubMed, and Embase. The searched terms were quality, status, situation, issue, deficiency, trials, China, and Chinese. The full search strategies which tailored according to the characteristic of the above databases were listed in supplementary material 2. We collected studies that reported problems from all aspects of clinical trials in China. In addition, we reviewed the references of the included studies to obtain relevant studies. Simultaneously, we searched grey literature and the reference lists of identified studies.

### Study selection

All retrieved studies were imported into Endnote (X9) software, and then, duplicated studies were removed. Two reviewers (J-F and XB-L) independently screened the titles and abstracts to identify relevant studies in accordance with the inclusion and exclusion criteria. Subsequently, two reviewers (J-F and XB-L) downloaded the full-text of all possibly relevant studies for further assessment. Then, two reviewers (J-F and XB-L) cross-checked the included studies, and a third reviewer (YG-Z) was involved in case of disagreement.

### Data extraction

A standardized data extraction form was designed in advance. After identifying all eligible studies, two authors (J-F and XB-L) independently extracted the data according to the data extraction form. The extracted data included (1) basic information (title, first author, published journal, year, and others) and (2) types of included studies, reported problems, specific stage the problem was related to, the criteria used to evaluate the problems, and suggestions for improvement. Then, the two reviewers (J-F and XB-L) analyzed the data. Two reviewers (J-F and XB-L) resolved all discrepancies through team discussion.

### Statistical analysis

The level of agreement between reviewers was determined by the Kappa value using SPSS 25.0 software package as follows: fair agreement (0.40–0.59), good agreement (0.60–0.74), and excellent agreement (0.75 or more). We qualitatively summarized the primary outcome data. The enumeration data were described by the frequency and composition ratio. The results were summarized via tabulation.

**Results**

**Included studies and characteristics**

We retrieved a total of 25,812 articles, of which 7173 were duplicates and thus removed. After reviewing titles and abstracts, 157 articles were retained for full-text review. After evaluating full texts, we finally included 90 [7–96] articles, which were published in 58 domestic and foreign journals. The included studies were published from 2000 to 2021. Seventy-one [7–19, 21–24, 28–31, 34, 35, 39–48, 50–52, 54–57, 60–65, 69–74, 76–89, 92–96] were full-text Chinese with English abstract studies; 19 [20, 25–27, 32, 33, 36–38, 49, 53, 58, 59, 66–68, 75, 90, 91] were full-text Chinese studies. The Kappa statistic of 0.82, 0.78 reflected excellent agreement between two reviewers for selecting studies and extracting data. The PRISMA flow diagram of the literature search is presented in Fig. 1. The full list of all 90 papers is showed in supplementary material 3.

Table 1 shows the main characteristics of the included studies. There were 50 studies with 0–5 citation counts (55.56%), 18 studies with 5–10 citation counts (20%), 9 studies with 10–15 citation counts (10%), and 13 studies with more than 15 citation counts (14.44%). Eight (8.89%) studies were conducted by a supervision

department, 38 (42.22%) by organizations with GCP qualification, and 44 (48.89%) by third parties.


**Problems in clinical trials**

**Problems in the ethical review process of clinical trials**

GCP guidelines require that medical institutions conducting clinical trials should establish an ethics committee. The ethics committee, an organization to review ethical issues and supervise clinical trials, is established based on relevant domestic and international laws and regulations. The ethics committee is responsible for ensuring the dignity, rights, safety, and health of subjects and monitoring the conduction of clinical trials in accordance with ethical principles. In recent years, increasing clinical trials have been conducted in China, and ethical review plays an important role in the implementation of clinical trials. Nevertheless, there were many problems in the ethical review process of clinical trials in China. We included 14 [7, 11, 13, 17, 19–22, 24–27, 29, 30] studies which mentioned problems in the ethical review process of clinical trials (Table 2).

**Problems in the registration process of clinical trials**

The International Committee of Medical Journal Editors (ICMJE) requires that all clinical trials must be internationally registered before publication. Otherwise, the



**Fig. 1** The PRISMA flow diagram for the identification of studies

**Table 1** Basic characteristics of included studies

Type	Clause	Number (article)	Rate (%)
Citation frequency	0–5	50	55.56
	5–10	18	20
	10–15	9	10
	> 15	13	14.44
Research resource	Supervision department	8	8.89
	Organizations with GCP qualification	38	42.22
	Third parties	44	48.89

results of the trials cannot be published [97]. In 2004, China established a Chinese clinical trial registration center in West China Hospital of Sichuan University based on the World Health Organization International Clinical Trials Registration Platform [98], which accepted the worldwide registration of clinical trials. Although most clinical trials conducted in China were registered, there were some problems with the registration process. We included 7 [9, 10, 12, 14–16, 18] studies which mentioned problems in the clinical trial registration process, and the results are showed in Table 3.

#### **Problems in the implementation process of clinical trials**

The authenticity, reliability, and integrity of clinical trials are critical for determining the credibility of clinical trial results. Therefore, strengthening the standardized management of clinical trials is significant. Moreover, the evidence from high-quality clinical trials is used to evaluate new clinical interventions. Therefore, the quality of clinical trials directly affects the health of patients. In 2015, the CFDA reviewed the clinical data of 1622 projects, and the results showed that the quality of clinical trials conducted in China needed to be improved. At present, there were still several problems with the clinical trial implementation process regarding informed consent, protocol execution, quality control, drug

management, data recording, adverse event management, biological sample handling, clinical research coordinators, and clinical trial contracts. Finally, we included 54 [8, 19, 23–25, 28, 31–61, 63, 64, 66, 69, 70, 74–81, 84–87] studies which mentioned problems in the clinical trial implementation process, and the results are showed in Table 4.

#### **Problems in the reporting process of clinical trials**

The reporting of clinical trials is a summary of the design and implementation process written in accordance with reporting guidelines. The reports enable readers to understand the entire trial process and interpret the results. Additionally, the reporting of clinical trials is imperative for evaluating the effectiveness and safety of the intervention. The implementation of reporting guidelines of clinical trials is an important process to ensure the quality of reporting. In our study, we identified 19 [62, 64, 65, 67, 68, 71–73, 82, 83, 88–96] studies related to several problems in the reporting process of clinical trials (Table 5).

#### **Discussion**

Recently, evidence-based medicine helps to standardize the classification of health care outcome research. Randomized control trials (RCTs) are standard trials designed to verify the efficacy of a certain intervention.

**Table 2** Problems in the ethical review process of clinical trials

Subject	Number	Item
Ethics committee configuration	1	Unreasonable number and composition of the ethics committee [11, 13, 20, 24, 26, 30]
	2	Inadequate capacity of ethics committee members [7, 17, 26, 27, 29, 30]
Implementation	3	No review standards and norms [22, 26]
	4	Incomplete review and nonstandard records [21]
	5	Nonstandard documentation and qualification management [19]
	6	Ignoring follow-up reviews and ethical acceptance check [22, 27]
	7	No rigorous program review [25]
	8	Inadequate consideration of ethical issues (such as subsidy for participants, wash-out time, procedures for reporting serious adverse events) [25]
	9	Insufficient ethical consciousness of researchers [22]

**Table 3** Problems in the registration process of clinical trials

Subject	Number	Item
Researcher	1	Weak registration awareness [14]
	2	Unregistered protocol before implementation [14, 16]
Research	3	Non-standard or incomplete research protocol [9, 10, 12, 18]
	4	Lack of normative data management system [15]
	5	No claims of sharing raw data and superabundant registration [15]

The results of high-quality RCTs provide the most reliable evidence regarding the efficacy of healthcare interventions [99–102]. In general, *GCP* assures that the data and results are credible and protect the rights and integrity of subjects. The country issued a series of laws and regulations related to the registration and approval of new drugs in 1999, and *GCP* (issued in 2003) has become a formal implementation requirement of clinical trials of drug in China. However, in China, problems regarding the design, implementation, and reporting of clinical trials still exist. Understanding current clinical trial issues is important for the development of high-quality clinical trials in the future. Therefore, we conducted the current systematic review to summarize the problems in the entire trial process and provide suggestions for high-quality clinical trials. A total of 90 studies related to the quality of clinical trials conducted in China were included. Among them, 42.22% were conducted and summarized by clinical trial institutions (*GCP* centers) or regulatory agencies based on completed clinical trials, thereby reflecting the actual problems in clinical trials of China. The results showed that the current problems in clinical trials of China mainly involved four sections, including ethics review, clinical trial registration, implementation, and reporting.

Before the commence of clinical trials, the investigators should carry out ethical review to ensure the rights and interests of subjects [103]. Our study identified various issues regarding ethics committees in China, including an insufficient numbers, structure, or capacity of members and inadequate implementation, supervision, acceptance, and audit. Considering this situation, an ethics committee training institution should be organized to provide specialized training and academic networks for the ethics committee members. Second, the regulatory process of the ethics review committee should be improved, the extent of supervision by the ethics review committee should be strengthened, and the ability of ethics review members should be enhanced. Finally, the internal members of the ethics committee should clarify the responsibility of all parties and strengthen communication and cooperation to improve the overall ability.

Generally, the results of clinical trials and levels of evidence are helpful for clinical decision-making. However,

low-quality RCTs usually provide poor-quality evidence, which might mislead clinicians. For instance, RCTs with inappropriate allocation concealment tend to exaggerate treatment effects [104, 105]. Clinical trial registration is an important measure to improve the transparency of clinical trials. Through registration of clinical trial protocols, publication bias and duplicate research can be reduced [106]. Moreover, reporting can increase the reproductivity of the research process and credibility of results. Our results showed that, in Chinese clinical trials, unregistered and post-registered phenomenon were common. Therefore, clinical investigators need to understand the importance of clinical trial registration and register their clinical protocols in advance at relevant registries (e.g., <http://www.chictr.org.cn/index.aspx>, <https://clinicaltrials.gov/>, <https://www.isrctn.com/>, etc.).

Clinical trials are used to determine the efficacy and safety of new interventions. Problems in the implementation of clinical trials affect the quality of clinical trials and reliability of results. This study identified several problems in the implementation of clinical trials, such as processes related to informed consent, program implementation, quality control, drug management, data recording, adverse event management, and biological sample handling. The poor quality of clinical trials is mainly due to the inadequate design and implementation of the trial protocol. International experts reveal that the impact of clinical trial design on the quality of clinical trials is even more important than the quality management system. To ensure the scientific integrity of trial protocols, the experienced methodologists and statisticians should participate in clinical trial design and statistical analysis. Additionally, clinical investigators should join in developing trial protocols and proposing timely amendments to any issues. During the implementation of clinical trials, strictly adhering to trial protocols is a prerequisite for ensuring the quality of clinical trials. However, some investigators may violate the protocol, which may induce bias in clinical trials. Clinical trial institutions should improve the quality control system and establish relevant standard operating procedures (SOPs). Moreover, investigators should receive training on SOPs to guarantee that all investigators fully understand and strictly follow the protocol before the trial. Improvement of scientific research ability and strengthening

**Table 4** Problems in the implementation process of clinical trials

<b>Informed consent</b>		
Subject	Number	Item
Design	1	Templated content [58, 84]
	2	Insufficient information and incorrect version [38, 40, 54, 58, 69, 76, 86]
Implementation	3	Incomprehensive description of insurance and compensation [8, 40, 84]
	4	Unreviewed and unapproved by the ethics committee [70, 86]
	5	Nonstandard informed consent signing and writing [24, 38, 54, 63, 85, 86]
	6	Lack of contact information and signing date [32, 80, 84]
	7	Deficient notification [58]
	8	Selective or induced notification [28, 38, 58, 70, 85, 86]
	9	Inappropriate place of notification [85]
	10	Unprovided copy of the informed consent to the patient [32, 41, 54, 84]
	11	Absence of informed consent signed by screening subjects [80]
	12	Informed consent process is not reflected in the original medical record [32]
Protocol execution		
Subject	Number	Item
Implementation	1	Unstrict execution of inclusion and exclusion criteria [19, 25, 32, 46, 63, 64, 75, 77, 78, 80, 81]
	2	Administration of drugs not in accordance with dosage specified in the protocol [77, 80]
	3	Premature or delayed assessment [32, 46, 57, 60, 75, 80]
	4	Time-overlapping between informed consent, screening, enrolment, and administration of drugs [24]
Record	5	Taking unspecified drugs and not recorded or not recorded on time [24]
	6	Incomplete documentation of clinical trials process [39]
	7	The signing time of the corresponding task assignment form, training record form, and the protocol signing page did not conform to the actual situation when the researchers change or the task assignment changes [24]
Quality control		
Subject	Number	Item
Inspectors	1	Inadequate execution of tertiary quality controls [44, 50, 61, 87]
	2	Insufficient competence and responsibility of the inspectors [36, 49, 56, 87]
Drug management		
Subject	Number	Item
Implementation	1	Nonstandard management in experimental drugs receipting, distribution, storage, recycling, and destruction [24, 42, 53, 59]
	2	No standard for the label of experimental drugs [59]
	3	Nonstandard records of drug administration [63, 79]
	4	The information of drug administration forms does not match with the records in original medical reports and case report forms [24, 79]
	5	The records do not present the actual dosage of drugs [32]
	6	The drug dosage and specifications recorded in drug release form are not matched with the reality [32, 80]
	7	Researchers lack knowledge on quality management practices in drug clinical trials [33, 47, 80]
Data record		
Subject	Number	Item
Implementation	1	Nonstandard record and revision of case report form [25]
	2	Missing or incomplete records of drug combination [32, 57]
	3	Inconsistent data records with primary material [32, 51, 77, 80]
	4	Data is not recorded in the medical records or not recorded in time [25]
	5	Data is untraceable, irregular, omitted, and concealed records of adverse events in trials [32, 80]

**Table 4** Problems in the implementation process of clinical trials (Continued)

Informed consent		
	6	Incomplete records of the reports [32, 74]
Adverse events management		
Subject	Number	Item
Judgment	1	Absence of risk prediction, prevention mechanism, and treatment for serious adverse events in the study protocol [55]
	2	Confuse clinical trials with clinical treatment [35]
	3	Absence of report on adverse events [55]
	4	Delayed time in submission of report on adverse events [23, 34, 35, 55]
	5	Misjudgment of abnormal inspection results [35]
	6	No dynamic observation on inspection results [35]
	7	Misjudgment of the causal relationship between adverse events and experimental drugs [35]
Record	8	Nonstandard report of adverse events, including deferred report and improper writing of report form [34, 55]
	9	Incomplete original records [35]
	10	Incomplete receipt collection [34]
	11	Special circumstances are not noted [34]
Biological sample handling		
Subject	Number	Item
Implementation	1	Inadequate collection, storage, transportation, and handover records of biological sample [24, 77]
Record	2	Disorder timeline of records in sample collection, inspection, and audit process [24]
Clinical research coordinators		
Subject	Number	Item
Coordinator	1	Uneven ability of clinical research coordinators [48, 66]
System	2	Imperfect construction of management organization system [37, 48]
	3	Incomplete training and assessment mechanism [37, 66]
	4	Lacking unified management system [37, 66]
Clinical trials contract		
Subject	Number	Item
Contract	1	No standards and principles for reviewing clinical trials protocols [45]
	2	No legal professional participant in review of clinical trials contract [31]
	3	Unclear injury compensation liability of participants [31, 43, 45, 79]
	4	Unreasonable clauses involving termination, confidentiality, and intellectual property ownership [31]
	5	Low purchase rate of clinical trials insurance cause the rights and interests of subjects and researchers cannot be fully protected [52]
	6	Trials contracts contain missing clauses, including description of clinical trials costs, contract signatory, and responsibilities of all parties [31]

**Table 5** Problems in the reporting process of clinical trials

Section	Number	Item
Abstract	1	Insufficient report of title, trials design, allocation concealment method, and trials registration [82, 88]
Methods	2	Insufficient description of random allocation sequence, allocation concealment, blinding, data analysis, and the processing of missing data in method section [62, 64, 65, 67, 71–73, 83, 88–96]
Results	3	Low report rate of subject's flow chart and compliance [62, 73, 88]
Discussion	4	Insufficient analysis of the causes of major adverse events [71]
	5	Few studies mention and analyze the limitations of trials in detail [68]
Other	6	Studies published in Chinese have low rate of registration and incomplete outcome [65]

supervision are important measures to avoid potential bias and improve the quality of clinical trials in China.

When the investigators report the clinical trials, investigators should report in accordance with Consolidated Standards of Reporting Trials (CONSORT) or other guidelines related to clinical trial reporting. Reporting clinical trials in accordance with reporting guidelines could enable readers to understand a trial's conduct and to assess the validity of its results [107]. Therefore, RCTs should be reported adhering to the CONSORT, observational studies should be reported referring to strengthening the reporting of observational studies in epidemiology (STROBE) [108], and the protocol of RCTs should comply with Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) [109]. Journals should pay more attention to the reporting quality of clinical trials and demand authors to obey to the reporting guidelines [62]. Thereby, the authors could report their findings in a transparent and standardized way, provide readers with accurate information regarding clinical trial processes, facilitate peer review, and enhance the quality of reporting. In addition, the guideline to strengthen the quality of clinical trials, or to establish evidence ecosystem can help the quality of clinical trials [110, 111].

### Limitations

There are several limitations of this systematic review. Firstly, due to the disciplines in most studies that were scattered, only thirteen studies could be divided into different disciplines. So, it is difficult to analyze the included studies by disciplines. Secondly, since all the included studies were secondary research, a certain bias may exist. Thirdly, among the included studies, the problems mainly focused on the RCTs, which may be not applicable to other types of clinical trials. Fourthly, the current study do not include study which is performed to assess quality of trials focusing in a specific disease or a type of study, so further studies are needed. Lastly, we included only Chinese language and English language papers, so the language bias may exist [112].

### Conclusions

In conclusion, the quality problems of clinical trials in China still exist, which includes problems related to the entire clinical trial process, including ethical review, registration, implementation, and reporting. Due to the limited quantity and quality of included studies, our conclusions need to be verified by high-quality studies.

### Abbreviations

CFDA: China Food and Drug Administration; GCP: Good Clinical Practice; PRISMA: Preferred Reporting Items and Systematic Reviews and Meta-Analysis; ICMJE: International Committee of Medical Journal Editors; RCTs: Randomized control trials; SOPs: Standard operating procedures; CONSORT: Consolidated Standards of Reporting Trials;

STROBE: Strengthening the Reporting of Observational Studies in Epidemiology

### Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13063-022-06281-1>.

**Additional file 1: Supplementary material 1:** Completed PRISMA checklist.

**Additional file 2: Supplementary material 2:** All search strategy.

**Additional file 3: Supplementary material 3:** The full list of all 90 papers

### Acknowledgements

Not applicable

### Authors' contributions

YG-Z conceived this study and decided on the framework for analysis. J-F contributed to drafting the manuscript, and all authors conducted the searches, data extraction, and analysis. All authors have read and approved the final manuscript for submission.

### Funding

This study was supported by National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University (Z2018B16, Z20191009), and was partly supported by National Natural Science Foundation of China (82004213, 82174227) and Project of Sichuan Provincial Department of Science and Technology (2021YFH0191).

### Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

### Declarations

#### Ethics approval and consent to participate

Not applicable

#### Consent for publication

Not applicable

#### Competing interests

The authors declare that they have no competing interests.

#### Author details

<sup>1</sup>Department of Periodical Press, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China. <sup>2</sup>School of Health Preservation and Rehabilitation, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China. <sup>3</sup>Chinese Evidence-based Medicine Center, West China Hospital of Sichuan University, Chengdu, Sichuan, China. <sup>4</sup>Nursing Key Laboratory of Sichuan Province, Chengdu, China.

Received: 25 May 2021 Accepted: 5 April 2022

Published online: 23 April 2022

### References

1. Wang X, Chen J, Li J, Wang B, Zhou L, Li Y, et al. Development and changes of quality control of clinical trials in China. *Chin J Evid Based Med*. 2018; 18(08):776–82.
2. Wu T, Li Y, Liu G, Li J, Deng S, Du L. The strategies of improving the quality of clinical studies in China. *Chin J Evid Based Med*. 2010;10(11):1243–8.
3. Yao C. Clinical trial in China: The status and challenge of data management and statistical analysis. *J Evid Based Med*. 2018;11(1):3–6. <https://doi.org/10.1111/jebm.12295>.
4. Li J, Sun Z, Gao R, Peng Z. Present situation and development direction of drug clinical trial in China. *Chin J Clin Pharmacol*. 2013;29(06):473–6.
5. Taichman DB, Backus J, Baethge C, Bauchner H, de Leeuw PW, Drazen JM, et al. Sharing clinical trial data: a proposal from the International Committee

- of Medical Journal Editors. *JAMA*. 2016;315(5):467–8. <https://doi.org/10.1001/jama.2015.18164>.
6. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. *BMJ*. 2021;372:n160. <https://doi.org/10.1136/bmj.n160>.
  7. Tian L, Zhang H. Problem analysis and solution after ethical review in clinical trial. *Chin J Clin Pharmacol*. 2019;35(06):584–6.
  8. Feng L. Survey of subjects' understanding of informed consent in drug clinical trials. *Chin J New Drugs*. 2018;27(24):2911–5.
  9. Lu P, Liao X, Xie Y, Wang Z. The necessity and feasibility of establishing technical specifications for registry of Chinese medicine clinical study. *Chin J Integr Tradit Western Med*. 2015;35(01):14–8.
  10. He Q, Kuang J, Tao M, Lu Y, Xiao W, Gao T, et al. Analysis and reflection on registration of Chinese clinical research on COVID-19. *Pharm Clin Chin Materia Medica*. 2020;11(5):1–4.
  11. Gao R, Tang J, Fang X, Lei M, Zhang Q. Perspectives on the implementation of ethics committee's responsibilities from drug clinical trial data inspection. *Chin J New Drugs*. 2019;28(20):2513–7.
  12. Zhao S, Zhang B, Chang X, Liu Y, Li Y, Li J. Analysis of registered drug clinical research of coronavirus disease 2019. *Chin J Hosp Pharm*. 2020;40(14):1499–504.
  13. Chen S. Problems and countermeasures in ethical review system of clinical research in China. *Soft Sci Health*. 2019;33(11):66–70.
  14. Wu T, Minawaer A, Hao Y, Kong X, Chen S, Li Y. The past 10 years of clinical trial registration in China: status and challenge. *Chin J Evid Based Med*. 2018;18(6):522–5.
  15. Wu T, Minawaer A, Bian Z, Shang H, Yang L, Hao Y, et al. An investigation based on registered clinical trials on Chinese clinical trial registry for exploring the factors of impacting quality of clinical trials. *Chin J Evid Based Med*. 2018;18(06):526–31.
  16. Shen W, Wu X, Wang G, Liu J. Common problems and solutions in the design of TCM clinical trial research programs. *Acta Chin Med Pharmacol*. 2015;43(04):1–4.
  17. Geng W, Qin D, Dai M, Jiang Y. Problems and countermeasures of ethical review and supervision of high-risk medical technologies: take gene editing technology as an example. *Chin Med Ethics*. 2020;33(6):695–8.
  18. Xiang Y, Zeng C, Huang X, Wang X, Zhang Z, Yang G. Analysis of clinical trial registration information of COVID-19 in China. *Chin J Clin Pharmacol Ther*. 2020;25(2):135–40.
  19. Ding Z, Cong L, Wu B. Study on the common problems of and countermeasures for the supervision of institutions for drug clinical trial. *Chin Pharm Affairs*. 2018;32(03):299–304.
  20. Zhang L, Zhao S, Guo C. Problems and countermeasures of drug clinical trials in China. *Chin J Clin Ration Drug Use*. 2018;11(04):162–3.
  21. Wu C, Cao G, Wu R, Zou H. Ethics committee's management of noncompliance/violation or protocol deviation report in clinical research. *Chin Med Ethics*. 2018;31(03):328–31.
  22. Liu D, Zeng S, Deng F, Zhou J. Discussion on the problems and suggestions in ethical review of clinical scientific research projects in China. *Chin Med Ethics*. 2018;31(07):829–32.
  23. Liu Q. Investigation and analysis of current status of ethical review of serious adverse events in clinical trials in Jiangsu Province: NanJin Medical University; 2017.
  24. Zhao T, Ma L, Wang H, Xiang P. Common problems and countermeasures in the implementation of drug clinical trial project. *China Modern Doctor*. 2017;55(8):146–8.
  25. Zhao J, Zhang X, Shen L. Ethical problems and analysis of countermeasures in drug clinical trials. *J Qiqihar Med Univ*. 2016;37(21):2748–9.
  26. Yan X, Liu Z, Chen Y, Wang H. The existing problems in the construction and development of medical ethics committee. *Chin Remedies Clin*. 2016;16(03):363–5.
  27. Li Y. Key points of ethical review in drug clinical trials. *China Health Care Nutr*. 2016;26(16):136–7.
  28. Bai C, Fan X, Ren P, Li N. Comparison and analysis of issues existing in informed consent forms of clinical trials sponsored by foreign and domestic enterprises. *Chin J New Drugs*. 2015;24(15):1750–3.
  29. Wang H, Wang C, Li S. Problems and countermeasures for the ethical review of drug clinical trials. *Chin Hospital Manage*. 2015;35(12):75–6.
  30. Chen Y, Yan X, Wang H. Research on problems and countermeasures of drug clinical trials. *Soft Sci Health*. 2015;29(11):691–4.
  31. Cao Y, Cao G, Zhang J, Wu C, Zhan H, Mao Y. Research on problems and countermeasures of the management of clinical trials' contracts in medical institutions. *Chin J New Drugs*. 2019;28(24):2997–3000.
  32. Li G, Min J, Wang Y, Zhao X, Xia Y. Problems and countermeasures of quality control of drug clinical trial items. *Pharm Care Res*. 2019;19(05):392–4.
  33. Hou Y, Zhao Q. Analysis of common problems and measures in the process of drug clinical trial. *Electron J Pract Clin Nurs Sci*. 2019;4(38):123.
  34. Jin H, Zhang X, Mo X, Cui Y, Zhang G. Problems and countermeasures of drug clinical trial SAE report. *Chin Hosp Pharm J*. 2017;37(15):1530–2.
  35. Zeng L, Pan X. Analysis of adverse event records in quality control of drug clinical trial institutions. *Chin J Pharmacovigilance*. 2018;15(11):693–5.
  36. Feng C, Jiang Y. Analysis of common problems and measures in the process of drug clinical trial. *Nurs Integr Tradit Chin Western Med*. 2017;3(03):137–9.
  37. Feng C, Jiang Y. Problems and countermeasures in the management of drug clinical trial coordinators. *J Front Med*. 2018;8(29):390–2.
  38. Ceng H, Wang Q. Thinking on the writing of informed consent for drug clinical trial. *J Med Inform*. 2016;29(31):258–9.
  39. Gao C, Chen X, Wang J, Li Y, Tian S, Zhu C. Managerial experience in clinical research process of Chinese medicine. *Guiding J Tradit Chin Med Pharm*. 2017;23(18):6–8.
  40. Liu D, Zeng S, Deng F, Zhou J. Existing problems and solution of informed consent in clinical research. *Chin Med Ethics*. 2018;31(06):732–5.
  41. Liu F, Deng G, Li X, Wang G. Investigation and analysis of existing problems in clinical trials of drugs and countermeasures. *Chin J New Drugs*. 2017;26(17):2059–63.
  42. Liu F, Deng G, Li X, Wang G. Discussion on the problems and countermeasures in the management of experimental drugs. *China Med Herald*. 2017;14(20):128–31.
  43. Fan H, Wang H, Zhang H. Problems and countermeasures in contract management and fund management of drug clinical trial. *Chin J Med Sci Res Manag*. 2018;31(03):232–5.
  44. Hu J, Zhang X, Jiang Y, Sun Y, Li Y, Tian G, et al. Developing status of clinical research in China and the existing problems, strategies and practices of clinical research of traditional Chinese medicine. *Modernization Tradit Chin Med Materia Medica World Sci Technol*. 2018;20(08):1417–21.
  45. Liu J, Mi F, Zhao W, Zhang T, Chu N, Cai C. Common problems and countermeasures of clinical trial agreement. *Hosp Adm J Chin People's Liberation Army*. 2018;25(02):135–6.
  46. Li J, Shang H, Zhao C. Problems discovered in drug clinical trial quality monitoring and countermeasures: including problems of post-marketing reevaluation of Chinese patent drugs. *Chin J New Drugs*. 2019;28(18):2184–8.
  47. Chen L, Zhang S. Analysis of quality management status and existing issues in the drug clinical trial institution in our hospital. *China Health Ind*. 2017;14(10):160–1.
  48. Liu L, Zhou J. Sources, responsibilities, problems and countermeasures of clinical research coordinators in clinical trials. *J Int Pharm Res*. 2018;45(07):512–6.
  49. Mijiti B, Mohemaiti P. Problems and countermeasures in the implementation of quality management standard for drug clinical trials in general hospitals. *Xinjiang Med J*. 2016;46(12):1590–2.
  50. Peng P, Yuan W, Hu Y, Tang J, Jiang J. Analysis of regulatory issues of adverse events in drug clinical trials. *Chin J Clin Pharmacol Ther*. 2018;23(01):78–82.
  51. Peng P, Yuan W, Hu Y, Tang J, Zhu L, Jiang J. Analysis of issues in drug clinical trials. *Chin J New Drugs Clin Remedies*. 2015;34(05):339–42.
  52. Peng P, Yuan W, Hu Y, Tang J, Zhu L, He M, et al. Discussion on the issues and countermeasures in clinical trial insurance. *Chin Med Ethics*. 2017;30(03):328–30.
  53. Chen Q, Liang D. Problems on the management of hospital drug clinical trial and analysis of measures. *Capital Food Med*. 2015;22(04):14.
  54. Zhao S, Liu X, Fu Z, Jiang M. Analysis of problems in clinical informed consent. *Chin J New Drugs*. 2016;25(23):2692–5.
  55. Li X, Zhang X, Liu S, Liang W, Liu J. Problems and solutions of serious adverse event report in clinical research from perspective of ethics review. *Chin J New Drugs Clin Remedies*. 2017;36(07):393–6.
  56. Han X, Luo H, Zhang D. On problems and countermeasures of drug clinical trial data cleanup in China. *Chin Pharm Affairs*. 2018;32(07):853–7.

57. Hu Y, Tang J, Peng P, Yuan W. Thoughts on the quality of clinical trial of new drugs in China. *J Guangdong Pharm Univ.* 2019;35(02):279–84.
58. Xing X, Zhang J, Deng R, Wang X, Gao J. Reflections on informed consent in clinical trials. *Electron J Clin Med Lit.* 2019;6(82):188–9.
59. Liang Y, Lu J. Problems and countermeasures of drug management in clinical trials. *J Pract Med Tech.* 2015;22(04):440–2.
60. Huang A, Sun R, Wang Y, Li H, Xu K, Yang C, et al. Clinical trial data quality problems and improvement measures. *J China Japan Friendship Hosp.* 2015;29(04):224–7.
61. Peng Z, Wang C, Chen Y, Yang C, Xu W, Xu X. Problems and countermeasures for data verification of drug clinical trial. *Chin J Hosp Pharm.* 2018;38(21):2267–72.
62. Yu D, Xie Y, Liao X, Zhi Y, Jiang J, Chen W. Methodological quality and reporting quality evaluation of randomized controlled trials published in China Journal of Chinese Materia Medica. *China J Chin Materia Medica.* 2018;43(04):833–9.
63. He G, Zeng T, Zhang W, Zhang L, Zhang X, Xu C. Analyze the causes and control measures of common problems in clinical trials. *Chin J New Drugs Clin Remedies.* 2018;37(01):24–8.
64. Huang H, Shi Y, Qiu Y, Zhang S, Lu D, Li L, et al. Discussion on common problems and reporting standards of clinical trial protocols in China. *Chin J Med Sci Res Manag.* 2018;31(03):161–6.
65. Zhao H, Zhang J, Guo L, Yang F, Zhang M, Li Y, et al. The status of registrations, ethical reviews and informed consent forms in RCTs of high impact factor Chinese medical journals. *Chin J Evid Based Med.* 2018;18(07):735–9.
66. Li D, Jiang W. Problems and countermeasures in the management of external clinical trial coordinators. *Chin J Modern Nurs.* 2015;21(31):3834–5.
67. Chi H, Mao B, Wang L, Zhang Y. Journal of Chengdu University of Traditional Chinese Medicine: literature review of randomized controlled clinical trials. *West China Med J.* 2000;15(03):272–3.
68. Liu Q, Fang J. Attention should be paid to the statistical problem of medical clinical trial papers – the development of self-check list of statistical report items. *Natl Med J China.* 2007;87(34):2446–8.
69. Zheng J, Li Y. Research on protection of participants' rights and interests in clinical trials: a case study of a clinical trial agency of one 3A grade hospitals in Beijing. *Chin J New Drug.* 2015;24(15):1754–9.
70. Ji L, Zhao Q. Informed consent problems and countermeasures in drug clinical trial. *Chin Pharm Affairs.* 2015;29(04):412–6.
71. Chen L, Yao J, Chen J, Zhao L, Liang F. Quality evaluation of domestic literature reports on randomized controlled trial of acupuncture treatment of angina pectoris. *Modernization Tradit Chin Med Materia Medica World Sci Technol.* 2020;8:2710–6.
72. Wei M, Yang M, Zhang M, Wang W, Liu J. Assessment of clinical studies published in Chinese Journal of Infectious Diseases for 18 years. *Chin J Evid Based Med.* 2001;1(04):233–4.
73. Zhang M, Yang F, Li Y, Liu Y, Zhao M, Zheng W, et al. Quality evaluation of randomized controlled clinical trials in Chinese Journal of Integrated Traditional and Western Medicine. *Chin J Evid Based Med.* 2017;17(03):357–63.
74. Ji P. Quality management of clinical trials in China. *Chin J New Drugs.* 2013;22(1):13–6.
75. Liu Q, Wang Y, Chang T. Analysis of data recording defects in case report form of TCM clinical trial. *Chin J Inf Tradit Chin Med.* 2013;20(02):4–5.
76. Huang J, Shen Na, Liu H, Pu J, Hu J, Xiang Y. Informed consent information integrity research. *Pharm Care Res.* 2011;11(02):123–6. <https://doi.org/10.5428/pcar20110216>.
77. Li Q, Chen J, Zhang P, Zhou L. Clinical trial status and trends from quality management perspective. *Chin J New Drugs.* 2014;23(8):871–8.
78. Gao R, Wang A, Tang J, Fang X, Wang J. Perspectives on the implementation of sponsors' responsibilities from the drug clinical trial data inspection. *Chin J New Drugs.* 2019;28(8):973–7.
79. Gao R, Ning J, Wang A, Fang X, Zhang R. Perspectives on the implementation of responsibilities of drug clinical trial institutions from drug clinical trial data inspection. *Chin J New Drugs.* 2019;28(20):2518–23.
80. Gao R, Lv S, Li X, Lei M, Qian X. Perspectives on the performing of investigators' responsibilities from drug clinical trial data inspection. *Chin J New Drugs.* 2019;28(20):2508–12.
81. Han S, Kong Y, Sheng X, Zhao X, Zhou Y, Cui Y. Studies on current situation and strategies for subjects recruited of phase I clinical trial of drugs in China. *Chin J Clin Pharmacol.* 2016;32(18):1722–5.
82. Shang S, Yan Y, Wu X. Report quality assessment of randomized controlled trial abstracts from Chinese clinical journals. *Chin J Sci Tech Periodicals.* 2017;28(12):1121–7.
83. Pei X. Analysis of common defects in the clinical trial reports of traditional Chinese medicines. *Chin J New Drugs.* 2009;18(15):1391–3.
84. Luo X, Ma X, Wang Y, Duan J. Problem analysis and countermeasure of informed consent and ethical review of clinical study. *China Modern Med.* 2016;23(8):176–9.
85. Wu X, Wang L, Liu M, Yang X, Peng L, Zhang Y, et al. Analysis of the problem of informed consent in clinical trial. *Chin Med Ethics.* 2018;31(01):20–3.
86. Yan H. Common problems and analysis of informed consent in drug clinical trials. *Medical Community.* 2018;23:1.
87. Shen Y, Zhang Z, Zhang Q, Li C, Wang B. Analysis of defects and recommendation for "three levels quality control" system of clinical trials. *Chin J New Drugs Clin Remedies.* 2016;35(10):721–3.
88. Liu Y, Liang W. Reporting quality assessment of noninferiority and equivalence randomized controlled trials related to traditional Chinese medicine. *Chin J Evid Based Med.* 2011;11(03):336–40.
89. Bian Z, Li Y, Moher D. Further improve the reporting quality of clinical research in China. *Chin J Evid Based Med.* 2020;20(12):1365–6.
90. Xiang C, Zhang W, Chen X, Hu Hong, Wen J, Zhao C, et al. Analysis on quality of literatures related to randomized controlled trials on acupoint massage. *Chin Nurs Res.* 2020;34(12):2228–30.
91. Cui Z, Bian Y. Evaluation of methodological quality in clinical trials of traditional Chinese medicine. *Lishizhen Med Materia Medica Res.* 2019;30(09):2302–4.
92. Long D, Liu Z, Li X, Liu H. Quality assessment of randomized controlled trials related to traditional Chinese medicine published in Journal of Traditional Chinese Medicine in 2018. *Chin J Integr Med Cardio Cerebrovasc Dis.* 2021;19(11):1935–9.
93. He S, Zhang T, Sun W, Qiu Z. An assessment of methodological quality of multi-center randomized controlled trials of stroke treatments conducted in Chinese Mainland. *West China Med J.* 2020;35(6):673–8.
94. Yan S, He L, Liu B. Blinding assessment in randomized controlled clinical trials. *Chin J Evid Based Med.* 2014;14(05):631–5.
95. Li T, Wang G, Wang L. Common problems and countermeasures in clinical trials of traditional Chinese medicine. *Chin J Integr Tradit West Med.* 2006;26(04):298–302.
96. Gao X, Ma Y, Zeng Y, Li G. Issues in the clinical evaluation of the efficacy of traditional Chinese medicine. *Liaoning J Tradit Chin Med.* 2015;42(07):1217–9.
97. International Committee Of Medical Editors. Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication. [http://www.icmje.org/recommendations/archives/2008\\_urm.pdf](http://www.icmje.org/recommendations/archives/2008_urm.pdf).
98. Wang Y, Lei Y. Registration process and filling requirements of American clinical trial database. *Chinese J Inf TCM.* 2012;19(07):2–4.
99. Li X. The report of randomized controlled clinical trials (I). *Chin J Intervent Cardiol.* 2010;18(05):242.
100. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ.* 2010;340(mar23 1):c869. <https://doi.org/10.1136/bmj.c869>.
101. Altman DG, Bland JM. Statistics notes. Treatment allocation in controlled trials: why randomise? *BMJ.* 1999;318(7192):1209. <https://doi.org/10.1136/bmj.318.7192.1209>.
102. Alvarez F, Meyer N, Gourraud PA, Paul C. CONSORT adoption and quality of reporting of randomized controlled trials: a systematic analysis in two dermatology journals. *Br J Dermatol.* 2009;161(5):1159–65. <https://doi.org/10.1111/j.1365-2133.2009.09382.x>.
103. Zhang Y, Yang H, Luo X. Disputes and solutions of ethical review in drug clinical trials. *China J Tradit Chin Med Pharm.* 2019;34(09):3908–12.
104. Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. *BMJ.* 2001;323(7303):42–6. <https://doi.org/10.1136/bmj.323.7303.42>.
105. Pildal J, Hrobjartsson A, Jorgensen KJ, Hilden J, Altman DG, Gotzsche PC. Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. *Int J Epidemiol.* 2007;36(4):847–57. <https://doi.org/10.1093/ije/dym087>.

106. Tharyan P, Ghersi D. Registering clinical trials in India: a scientific and ethical imperative. *Natl Med J India*. 2008;21(1):31–4.
107. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. *Lancet*. 2001;357(9263):1191–4. [https://doi.org/10.1016/S0140-6736\(00\)04337-3](https://doi.org/10.1016/S0140-6736(00)04337-3).
108. von Elm E, Altman DG, Egger M, Pocock SJ, Gotsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med*. 2007;147(8):573–7. <https://doi.org/10.7326/0003-4819-147-8-200710160-00010>.
109. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Ann Intern Med*. 2013;158(3):200–7. <https://doi.org/10.7326/0003-4819-158-3-201302050-00583>.
110. He Y, Li J, Li Y, Jin R, Wen Q, Li N, et al. Strengthening the quality of clinical trials of acupuncture: a guideline protocol. *BMJ Open*. 2022;12(1):e053312. <https://doi.org/10.1136/bmjopen-2021-053312>.
111. Wang Q, Li N, Li J, He Y, Li Y, Zhong D, et al. A Protocol of a Guideline to Establish the Evidence Ecosystem of Acupuncture. *Front Med (Lausanne)*. 2022;8:711197. <https://doi.org/10.3389/fmed.2021.711197>.
112. Zhong D, Li J, Yang H, Li Y, Huang Y, Xiao Q, Liu T, Jin R. Tai Chi for Essential Hypertension: a Systematic Review of Randomized Controlled Trials. *Curr Hypertens Rep*. 2020;22(3):25. <https://doi.org/10.1007/s11906-020-1031-y>.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

